Stock Screener App

Gratuito -

Installare

195.15

6.14% 11.29

after-market

Dopo l'orario di chiusura: 195.15

Astrazeneca Plc (AZN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Perché AZN Giù? Forum Previsione Frazionamento azionario Storia dei dividendi

Astrazeneca Plc Borsa (AZN) Ultime notizie

China's CSPC Pharmaceutical Group to partner with AstraZeneca for renal disease drug - marketscreener.com

Abbisko Therapeutics Partners with AstraZeneca on Lung Cancer Th - GuruFocus

Abbisko teams with AstraZeneca on lung cancer trial after China IND clearance - Stock Titan

Why Astrazeneca (AZN) Dipped More Than Broader Market Today - Yahoo Finance

AstraZeneca PLC (AZN) Shares Fall 3.0% -- What GF Score of 76 Te - GuruFocus

AstraZeneca PLC Stock (AZN) Moved Down by 3.02% on Jul 1: What Investors Need To Know - TradingKey

AstraZeneca plc focuses on long-term growth as global pipeline expands - AD HOC NEWS

AstraZeneca admits 14,784 shares to London Stock Exchange - Investing.com

AstraZeneca PLC outlines long-term growth strategy as global drug portfolio expands - AD HOC NEWS

AstraZeneca admits 14,784 shares to London Stock Exchange By Investing.com - Investing.com Canada

AstraZeneca (NYSE: AZN) adds 14,784 employee scheme shares - Stock Titan

AstraZeneca (AZN) reports 1.55B total voting rights as of June 2026 - Stock Titan

REGAstraZeneca PLCAdmission of Further Securities to Trading - TradingView

AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors (Revised) - TradingView

ASTRAZENECA : Goldman Sachs reaffirms its Buy rating - marketscreener.com

BofA Forecasts In-line Q2 Sales, EPS for AstraZeneca; Buy Rating Maintained - marketscreener.com

Price to earnings forward of AstraZeneca PLC – SWB:ZEG - TradingView

ETFs Investing in AstraZeneca PLC Stocks - TradingView

AstraZeneca slides Tuesday, underperforms market - MarketWatch

AstraZenecaEnhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positive metastatic solid tumours - marketscreener.com

AstraZeneca PLC strengthened by Enhertu EU approval. JP Morgan reiterates buy rating on the stock - AD HOC NEWS

ASTRAZENECA : Sell rating from Deutsche Bank - marketscreener.com

RB Capital Management, LLC's AstraZeneca PLC(AZN) Holding History - GuruFocus

ASTRAZENECA : Receives a Buy rating from JP Morgan - marketscreener.com

AstraZeneca To Pay $34M In Texas Kickbacks Settlement - Law360

AstraZeneca Details Bone Health Data For Strensiq Successor - insights.citeline.com

AstraZeneca Advances Rare Bone Disease Pipeline While Enhertu Expands In Europe - Benzinga

Astrazeneca plc Datroway Recommends for Approval in EU for TNBC - marketscreener.com

AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors - TradingView

EU clears AstraZeneca (AZN) and Daiichi Sankyo’s Enhertu for HER2+ solid tumours - Stock Titan

AstraZeneca, Daiichi Sankyo Win EU Approval for Enhertu in HER2-positive Solid Tumors - marketscreener.com

AstraZeneca's Datroway and Enhertu candidates receive EU approval - Sharecast.com

AstraZeneca and Daiichi Sankyo’s Datroway recommended for EU approval in metastatic TNBC - DirectorsTalk Interviews

Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positive metastatic solid tumours - AstraZeneca

AstraZeneca’s Datroway gets EU panel backing for breast cancer By Investing.com - Investing.com UK

AZN Stock Quote Price and Forecast - CNN

Price to sales forward of AstraZeneca PLC – LSE:AZN - TradingView

AstraZeneca PLC AZN Q3 2025 Earnings Call Dallas Cowboys Schedule 2026 (4z9l16BTZU) - Mshale

Price to sales forward of AstraZeneca PLC ADR – BCBA:AZN.CI - TradingView

AstraZeneca highlights long-term oncology pipeline, shares supported by solid S&P 500 presence - Ad-hoc-news.de

AstraZeneca focuses on long-term oncology strategy, shares anchored in the FTSE 100 - Ad-hoc-news.de

The Breztri Aerosphere from AstraZeneca plctriple therapy aims at severe COPD - Ad-hoc-news.de

AstraZeneca cautious after EU panel vote, shares reflect Tavneos setback - Ad-hoc-news.de

AstraZeneca climbs Friday, outperforms market - MarketWatch

Why Did AstraZeneca (AZN) Stock Dip More Than the Market Today - Kavout | AI

Could This Clinical Milestone Reshape AstraZeneca’s (LSE:AZN) Future? - Kalkine Media

Daiichi Sankyo and AstraZeneca Announce Datroway Recommends for Approval in EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy - marketscreener.com

Jefferies names AstraZeneca a top pick ahead of pivotal heart drug readout - Yahoo Finance

AstraZeneca updates on pipeline and AI efforts, shares tracked by analysts - Ad-hoc-news.de

AstraZeneca's, Daiichi's Datroway recommended for further EU approval - London South East

AstraZeneca : Datroway recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy - marketscreener.com

Could AstraZeneca (LSE:AZN) Continue Leading the Healthcare Space? - Kalkine Media

Astrazeneca (AZN) Stock Price, News & Analysis $AZN - MarketBeat

Datroway recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy - AstraZeneca

ASTRAZENECA : Gets a Buy rating from Jefferies - marketscreener.com

AstraZeneca PLC Actuals & Estimates (LSE:AZN) - TradingView

AstraZeneca PLC ADR Unsponsored Brazilian Depositary Receipt Repr 0.1666 ADR - TradingView

Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note - sharewise.com

AstraZeneca PLC Actuals & Estimates (NYSE:AZN) - TradingView

AstraZeneca outlines next growth phase, shares sit on solid large-cap footing - Ad-hoc-news.de

Enterprise value to revenue forward of AstraZeneca PLC – LSE:AZN - TradingView

Enterprise value to EBIT forward of AstraZeneca PLC – LSE:AZN - TradingView

Enterprise value to EBITDA forward of AstraZeneca PLC – LSE:AZN - TradingView

Enterprise value to EBIT forward of AstraZeneca PLC ADR – BCBA:AZN.CI - TradingView

Price to earnings forward of AstraZeneca PLC ADR – BCBA:AZN.CI - TradingView

AstraZeneca reports positive Tagrisso data, shares stay in focus on NASDAQ - Ad-hoc-news.de

Enterprise value to revenue forward of AstraZeneca PLC ADR – BCBA:AZN.CI - TradingView

AstraZeneca PLC (AZN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Why is AstraZeneca (LSE:AZN) holding the spotlight as UK pharma stays firm today? - Kalkine Media

Can AstraZeneca PLC (AZN) Grow Its Rare Disease Portfolio Through Ultomiris Expansion? - Yahoo Finance

AstraZeneca and YMCA target cancer screening gaps in 75 communities - Stock Titan

AstraZeneca’s Next Chapter: What Is Driving Market Attention? - Kalkine Media

AstraZeneca operations and pipeline, shares anchored in FTSE 100 - Ad-hoc-news.de

NVS

$159.88

3.72%

MRK

$129.56

3.34%

NVO

$50.43

3.40%

AMGN

$374.15

3.55%

GILD

$131.27

4.21%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters